UBS Reiterates $40.00 Price Target for Pfizer
The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. UBS's price objective would suggest a potential upside of 12.01% from the company's current price.
from Biotech News
The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. UBS's price objective would suggest a potential upside of 12.01% from the company's current price.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments